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Background: Safety concerns regarding use of drug eluting coronary stents are related to late stent thrombosis, which is facilitated by incomplete 
endothelial stent coverage. Optical coherence tomography (OCT) is the new gold standard for intravascular imaging, enabling precise assessment 
of neointimal proliferation and stent endothelialization. The study aimed to compare by OCT the XIENCE® V everolimus eluting stent (DES; Abbot 
Vascular) and the bare metal stent Coroflex Blue® postdilated with the paclitaxel-eluting balloon Sequent Please® (BMS+DEB; B Braun Melsungen 
AG) with respect to endothelial coverage and neointimal proliferation.
Methods: Patients scheduled for elective PCI were openly randomized 1:1 to either XIENCE® or Coroflex Blue®+Sequent Please®. Angiographic 
follow-up (f/u) and OCT imaging with motorized pull-back at 1 mm/s were done 6 months after stent implantation. OCT endpoints were: (1) 
endothelial coverage, expressed as % of struts without coverage, and respectively (2) neointimal proliferation, given as neointimal volumetric 
proliferation within the whole stent and also as peak focal neointimal area proliferation. Volumetric analysis was done using OCT measurements on 
every 15th frame.
Results: Successful PCI with DES or BMS+DEB was carried out in 100 patients (52 DES and 48 BMS+DEB) and high-quality 6-month OCT was 
obtained in 84 patients (45 DES). Repeat PCI for restenosis was necessary in 3 patients (1 DES, 2 BMS+DEB, n.s.). OCT analysis showed significantly 
more neointimal proliferation calculated as proliferation volume/cm stent length in BMS+DEB (15.69 ± 7.6 mm3/cm vs. 11.21 ± 5.3 mm3/cm in 
DES, p = 0.002). However, we found no differences in maximal focal proliferation area (39.39 ± 13.5 mm2 in BMS+DEB vs. 36.95 ± 15.9 mm2 in 
DES, n.s.). Stent endothelialization was appropriate in both groups (uncovered struts: 4.1 ± 8.9 % in DES vs. 3.8 ± 7.3 % in BMS+DEB, n.s.)
Conclusions: Although DES resulted in a stronger overall inhibition of neointimal growth compared to BMS+DEB, both devices showed similar 
results regarding peak focal in-stent proliferation. OCT revealed a good endothelial coverage at 6 months, allowing to safely stop clopidogrel use in 
both study arms.
